You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 

CORPORATE

FSI SGR enters Kedrion share capital

The company continues with its growth and development strategy

read more 

CORPORATE

Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY

read more 

  1. EVENTS - 18-10-2018

    EIGHT, the global educational initiative on Hemophilia A and its treatment

    Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

    read more 

  2. EVENTS - 02-10-2018

    Kedrion Biopharma participates in the Mother and Child Conference in Moscow

    A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

    read more 

  3. CORPORATE - 05-09-2018

    Kedrion joins Rhesus Solution Initiative (RSI) symposium in Lagos

    Nigeria to advocate for Rh Disease universal eradication

    read more 

  4. EVENTS - 08-08-2018

    Kedrion Joins Annual PNS Conference on Neurology

    The company took part in the event with a booth and a delegation of 40 int’l guests

    read more 

Pages

For more information please contact: pressoffice@kedrion.com